uniQure N.V.
-
Ticker
QURE
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in Amsterdam, Netherlands
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.
REPORT RATINGS
5.0 / 5.0 (1)
uniQure N.V. reports have an aggregate usefulness score of 5.0 based on 1 reviews.
uniQure N.V.
Most Recent Responsibility Report
MOST RECENT
2023 Corporate Responsibility Report
Report Locked. uniQure N.V. has reached its limit for free report views.
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived uniQure N.V. Sustainability Report, uniQure N.V. Corporate Social Responsibility Report, uniQure N.V. CSR Report, uniQure N.V. Corporate Responsibility, uniQure N.V. CR Report, uniQure N.V. Citizenship Report, uniQure N.V. ESG Report, and uniQure N.V. Environmental Report online.